Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGIZE
NL-OMON56352Phase 3Recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in alpha thalassemia and beta thalassemia comparing Mitapivat with Placebo (2 arms). Primary endpoint: Hemoglobin response. Started Oct 2022; status: recruiting.
02
Drugs
mitapivat
03
Conditions
alpha thalassemiabeta thalassemia
Beyond the preview
Go deeper on NL-OMON56352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56352.